Moderna，Inc。
About Moderna，Inc。
1178 articles about Moderna，Inc。
-
Moderna said Thursday it plans to talk to regulators about the next steps after showing its next-generation candidate is more efficacious in adults than the biotech’s existing Spikevax COVID-19shot。 -
Moderna Announces Positive Phase3 Efficacy Data for mRNA-1283，the Company’s Next Generation COVID-19 Vaccine 6/13/2024 Moderna，Inc.announced that its Phase3trial of mRNA-1283，an investigational next-generation COVID-19vaccine，has met its primary efficacy endpoint，demonstrating non-inferior vaccine efficacy against COVID-19compared to Spikevax。 -
Moderna Announces Positive Phase3 Data for Combination Vaccine Against Influenza and COVID-19 6/10/2024 Moderna，Inc.announced that its Phase3trial of mRNA-1083，an investigational combination vaccine against influenza and COVID-19，has met its primary endpoints，eliciting a higher immune response than the licensed comparator vaccines used in the trial。 -
Moderna’s combination vaccine candidate for COVID-19and influenza outperformed licensed vaccines in older adults，according to late-stage results reported on Monday。 -
Moderna Files FDA Application for the JN.1 Targating COVID-19 Vaccine 6/7/2024 Moderna，Inc.（NASDAQ:MRNA）today announced that it has submitted an application to the U.S.Food and Drug Administration（FDA）for review of its Spikevax2024-2025formula， targeting the SARS-Cov-2variant JN.1。 -
Looking for a biopharma job？Check out the BioSpace list of 12 top companies hiring life sciences professionals like you。 -
Moderna on Thursday said its investigational mRNA-based therapy for methylmalonic acidemia has been selected for the FDA’s accelerator program for rare diseases，dubbed START。 -
Moderna's Investigational Therapeutic for Methylmalonic Acidemia（mRNA-3705）Selectby U.S.Food&Drug Administration for START Pilot Program 6/6/2024 Moderna，Inc.（NASDAQ:MRNA）today announced that the U.S.Food and Drug Administration（FDA）has selected mRNA-3705 for the Support for Clinical Trials Advancing Rare Disease Therapeutics（START）pilot program。 -
There are multiple ways biopharmas create inclusive workplaces for LGBTQ+employees，and they go beyond employee resource groups and benefits。 -
Analysts predict a booming year for mergers and acquisitions，powered by obesity drug sales and pressure from upcoming patent expirations。 -
Moderna&Merck Announce3-Year Data For mRNA-4157（V940）in Combination With KEYTRUDA（R） 6/3/2024 Moderna，Inc.（NASDAQ:MRNA）and Merck（NYSE:MRK）， known as MSD outside of the United States and Canada，today announced the first presentation of results from a planned analysis from the Phase2b randomized KEYNOTE-942/mRNA-4157-P201study。 -
Moderna Receives U.S.FDA Approval for RSV Vaccine mRESVIA（R）-May312024 5/31/2024 Moderna，Inc.announced that the U.S.Food and Drug Administration has approved mRESVIA，an mRNA respiratory syncytial virus vaccine，to protect adults aged60years and older from lower respiratory tract disease caused byRSV infection。 -
Moderna Receives U.S.FDA Approval for RSV Vaccine mRESVIA（R） 5/31/2024 Moderna，Inc.announced that the U.S.Food and Drug Administration has approved mRESVIA，an mRNA respiratory syncytial virus vaccine，to protect adults aged60years and older from lower respiratory tract disease caused byRSV infection。 -
Who Will the Next“Big Pharma”Players Be？ 5/29/2024 As AstraZeneca looks to climb toward the top of biopharma companies by revenue by the end of the decade，smaller companies are looking to join the ranks of the unofficial Big Pharma club。 -
Through its work with OpenAI，Moderna has given employees access to AI tools that aid their daily work and positioned itself for growth。 -
Looking for research associate jobs in the biopharma industry？Check out these five top companies hiring life sciences professionals like you。 -
Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting 5/22/2024 Moderna，Inc.announced that three abstracts on mRNA-4157，an investigational mRNA individualized neoantigen therapy，have been accepted for presentation at the 2024 American Society of Clinical Oncology Annual Meeting，which will be held May31-June4in Chicago，IL。 -
The European Patent Office last week upheld one of Moderna’s key patents，handing the biotech an important victory in its protracted COVID-19vaccine battle with Pfizer and BioNTech。 -
Looking for software development jobs in the biopharma industry？Check out these five top companies hiring life sciences professionals like you。 -
Moderna to Present at Upcoming Conferences in May/June 2024 5/13/2024 Moderna，Inc.，announced its participation in the following upcoming investor conferences: